With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

Eli Lilly has followed through on its plan to file for approval of its Alzheimer's disease candidate donanemab, and is planning to take on Biogen and Eisai with a head-to-head trial against their ...

Eli Lilly has chalked ... TRAILBLAZER-ALZ 2 trial, which showed that Kisunla slowed cognitive and functional decline by 35% compared with placebo on the integrated Alzheimer's Disease Rating ...

STX-478 is a once-daily oral, mutant-selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 clinical trial ... infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) revealed long-term study results indicating that over 80% of adults and adolescents with moderate-to-severe atopic dermatitis... ByInvesting ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

(Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner ...

Biogen BIIB announced that the FDA has approved a monthly maintenance dosing version for its intravenously (IV) administered ...

These findings complement advancements in clinical research, such as those spearheaded by Lilly Alzheimer’s research clinical trials, which focus on developing comprehensive treatment strategies for ...